Generated July 27, 2026 at 8:30 PM ET
· Covers July 27 trading day
· 10 of 219 ready 8-Ks selected
· AI-assisted overview
Today's filings featured two major M&A announcements: Luxfer Holdings agreed to be acquired by Wynnchurch Capital for $17.37 per share, and Vireo Growth will acquire Planet 13 in an all-stock deal. On the regulatory front, Nexalin Technology received a Nasdaq delisting notice for bid price non-compliance, while Camp4 Therapeutics obtained Australian TGA clearance for a Phase 1/2 trial, triggering a $50 million closing. Several litigation updates were disclosed: Katapult Holdings faces two shareholder lawsuits challenging its merger proxy, SELLAS Life Sciences lost an arbitration against 3D Medicines, and Vulcan Materials received negligible damages in a NAFTA tribunal ruling. Additionally, Target Hospitality closed a new $660 million ABL facility, replacing its prior $175 million credit line.
NXL
Nexalin Technology, Inc.
regulatory
negative
materiality 0.85
July 27, 2026, 5:25 PM ET
Nexalin receives Nasdaq delisting notice for bid price non-compliance; appeals hearing requested
- Nasdaq notified Nexalin on July 24, 2026 that it failed to regain compliance with $1.00 minimum bid price by July 20, 2026 deadline.
- Company also ineligible for second 180-day period due to not meeting $5M stockholders' equity initial listing requirement.
- Delisting and suspension scheduled for August 4, 2026 unless appeal stays process.
M&A
positive
materiality 0.90
July 27, 2026, 8:31 AM ET
Luxfer to be acquired by Wynnchurch Capital for $17.37/share in all-cash deal
- Purchase price of $17.37 per share represents ~30.7% premium to April 28, 2026 close of $13.29.
- Transaction unanimously approved by Luxfer Board; expected to close by February 26, 2027.
- Shareholders to receive cash; Luxfer shares to be delisted from NYSE upon closing.
PLNH
Planet 13 Holdings Inc.
M&A
positive
materiality 0.90
July 27, 2026, 7:45 AM ET
Vireo Growth to acquire Planet 13 in all-stock deal; 16.6% premium over 20-day VWAP
- Planet 13 shareholders to receive 0.015383618 Vireo shares per share; 16.6% premium over 20-day VWAP as of July 24, 2026.
- Transaction adds 36 dispensaries, 3 cultivation/production assets, and up to 2.3M sq ft of expandable capacity in Nevada.
- Pro forma Vireo expected to operate ~265 dispensaries across 15 states, becoming largest U.S. cannabis operator by dispensary count.
M&A
positive
materiality 0.85
July 27, 2026, 8:51 AM ET
Vireo Growth to acquire Planet 13 in all-stock deal; 16.6% premium to 20-day VWAP
- Each Planet 13 share to be exchanged for 0.015383618 Vireo subordinate voting shares.
- Consideration represents 16.6% premium to Planet 13's 20-day VWAP and 24% premium to July 24 closing price.
- Transaction adds 36 dispensaries, including Las Vegas superstore, 33 Florida dispensaries, and one Illinois dispensary.
PCSC
Perceptive Capital Solutions Corp
regulatory
positive
materiality 0.85
July 27, 2026, 8:10 AM ET
FDA approves Freenome's SimpleScreen CRC blood test; Abbott to commercialize, $100M milestone payment triggered
- SimpleScreen CRC detected colorectal cancer with 81.1% sensitivity and 90.4% specificity in the PREEMPT CRC study of over 48,000 patients.
- Freenome receives a $100 million milestone payment from Abbott for FDA approval; Abbott will exclusively commercialize the test in the U.S.
- Test meets Medicare coverage criteria and is expected to be incorporated into American Cancer Society guidelines by name.
CAMP
Camp4 Therapeutics Corp
regulatory
positive
materiality 0.85
July 27, 2026, 7:01 AM ET
CAMP4 receives Australian TGA clearance for CMP-002 Phase 1/2 trial; triggers $50M second closing
- TGA and HREC clearance to initiate first-in-human Phase 1/2 trial of CMP-002 for SYNGAP1-related disorder.
- Milestone triggers second closing of September 2025 private placement; up to $50M gross proceeds.
- Second closing expected on or about August 3, 2026; up to 32.7M shares (or pre-funded warrants) to be issued.
KPLT
Katapult Holdings, Inc.
litigation
negative
materiality 0.70
July 27, 2026, 4:59 PM ET
Katapult discloses two shareholder lawsuits challenging merger proxy; provides supplemental disclosures
- Two lawsuits filed July 15 and 16, 2026 in NY Supreme Court alleging proxy statement omissions; seek to enjoin merger or recover damages.
- Demand letters from purported stockholders received, making similar disclosure deficiency claims under federal securities laws.
- Special meeting of stockholders to approve merger remains scheduled for August 6, 2026 at 10:00 a.m. ET.
SLS
SELLAS Life Sciences Group, Inc.
litigation
negative
materiality 0.70
July 27, 2026, 4:35 PM ET
SELLAS loses arbitration against 3D Medicines; cash $138.3M as of June 30
- Arbitration claims dismissed; company ordered to pay ~$1.0M in legal fees.
- 3D Medicines to continue GPS development; $191.5M in potential milestones remain, including $13.0M disputed.
- Preliminary unaudited cash and equivalents $138.3M as of June 30, 2026.
litigation
negative
materiality 0.65
July 27, 2026, 5:27 PM ET
Vulcan Materials: NAFTA tribunal finds Mexico violated NAFTA but awards negligible damages
- Tribunal found Mexico violated NAFTA in several respects.
- Monetary damages awarded to Vulcan were negligible.
- Decision remains confidential until publicly available.
TH
Target Hospitality Corp.
debt
positive
materiality 0.70
July 27, 2026, 4:15 PM ET
Target Hospitality closes new $660M ABL facility, replacing $175M prior credit line
- New $660M asset-based revolving credit facility matures July 2031, nearly quadrupling prior $175M capacity.
- Borrowing cost reduced by up to 250 bps; interest at Term SOFR + 2.25%-3.00% based on leverage.
- Accordion feature allows incremental commitments up to $850M, subject to conditions.